Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBITDA (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of EBITDA data on record, last reported at -$38.0 million in Q3 2025.

  • For Q3 2025, EBITDA fell 44.76% year-over-year to -$38.0 million; the TTM value through Sep 2025 reached $40.8 million, up 138.85%, while the annual FY2024 figure was -$89.1 million, 13.95% up from the prior year.
  • EBITDA reached -$38.0 million in Q3 2025 per STOK's latest filing, down from -$23.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $112.9 million in Q1 2025 and bottomed at -$38.0 million in Q3 2025.
  • Average EBITDA over 4 years is -$16.2 million, with a median of -$25.2 million recorded in 2022.
  • The widest YoY moves for EBITDA: up 528.56% in 2025, down 44.76% in 2025.
  • A 4-year view of EBITDA shows it stood at -$25.1 million in 2022, then decreased by 6.8% to -$26.8 million in 2023, then soared by 59.76% to -$10.8 million in 2024, then crashed by 251.86% to -$38.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$38.0 million in Q3 2025, -$23.3 million in Q2 2025, and $112.9 million in Q1 2025.